Table 3.
Multivariate analysis for clinical outcomes, signs and symptoms at diagnosis, and long-term sequelae.
| COVID-19-Related Death (n 180) * | ||
| aOR (95CI) | p | |
| SARS-CoV-2 Ct | 0.84 (0.72–0.97) | 0.023 |
| Age | 1.25 (1.11–1.40) | <0.01 |
| Sex | 1.26 (0.21–7.55) | 0.80 |
| Time from COVID-19 onset to diagnostic swab | 1.03 (0.91–1.18) | 0.63 |
| Number of comorbidities | 2.44 (1.18–5.04) | 0.016 |
| Worst oxygen support None Low-flow wall oxygen-reservoir CPAP Intubation |
– 2.01 (0.14–8.98) 2.14 (0.65–7.01) 2.38 (0.94–6.06) |
- 0.61 0.34 0.068 |
| COVID-19 Severity (n 180) * | ||
| aOR (95CI) | p | |
| SARS-CoV-2 Ct | 0.95 (0.91–0.99) | 0.023 |
| Age | 1.08 (1.06–1.11) | <0.01 |
| Sex | 0.31 (0.17–0.58) | <0.01 |
| Time from COVID-19 onset to diagnostic swab | 1.04 (0.98–1.11) | 0.21 |
| Number of comorbidities | 1.6 (1.29–2.03) | <0.01 |
| Number of signs and symptoms at diagnosis (n 180) * | ||
| β (95CI) | p | |
| SARS-CoV-2 Ct | −0.060 (−0.10; −0.018) | <0.01 |
| Age | −0.013 (−0.32; 0.006) | 0.17 |
| Sex | −0.12 (−0.69; 0.44) | 0.67 |
| Number of comorbidities | 0.24 (−0.013; 0.50) | 0.063 |
| Time from COVID-19 onset to diagnostic swab | −0.12 (−0.62; 0.51) | 0.99 |
| 6-month sequelae in survivors (n 149) * | ||
| aOR (95CI) | p | |
| SARS-CoV-2 Ct | 0.90 (0.85–0.96) | <0.01 |
| Age | 1.02 (0.98–1.04) | 0.30 |
| Sex | 0.59 (0.26–1.35) | 0.21 |
| Time from COVID-19 onset to diagnostic swab | 0.98 (0.89–1.07) | 0.63 |
| Number of comorbidities | 1.01 (0.68–1.48) | 0.97 |
| Worst oxygen support None Low-flow wall oxygen-reservoir CPAP Intubation |
– 1.02 (0.37–2.82) 1.27 (0.37–4.38) 1.72 (0.41–7.29) |
- 0.97 0.71 0.46 |
* Asymptomatic patients without a defined time from COVID-19 onset to diagnostic swab collection were not included in multivariate analysis. CPAP, continuous positive airways pressure.